Adjunct Clinical Professor of Internal Medicine
[email protected]
Available to mentor
Christopher D Lao
Adjunct Clinical Professor
-
Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, Ribas A. Cancer, 2024 Jan 23;Journal ArticleA phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
DOI:10.1002/cncr.35200 PMID: 38261444 -
Oaknin A, Moore K, Meyer T, López-Picazo González J, Devriese LA, Amin A, Lao CD, Boni V, Sharfman WH, Park JC, Tahara M, Topalian SL, Magallanes M, Molina Alavez A, Khan TA, Copigneaux C, Lee M, Garnett-Benson C, Wang X, Naumann RW. Lancet Oncol, 2024 Apr 9;Journal ArticleNivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
DOI:10.1016/S1470-2045(24)00088-3 PMID: 38608691 -
Tawbi HA, Hodi S, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Gutiérrez EC, Rutkowski P, Gogas H, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Ratto B, Rodriguez S, Xu Y, Wang P, Dolfi S, Long G. Annales de Dermatologie et de Vénéréologie - FMC, 2023 Dec; 3 (8): a351 - a353.Journal ArticleNivolumab (NIVO) plus relatlimab (RELA) vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : résultats à 2 ans de RELATIVITY-047
DOI:10.1016/j.fander.2023.09.600 -
Huang R, Youssef G, Nelson T, Wen P, Forsyth P, Hodi FS, Margolin KA, Algazi AP, Hamid O, Lao CD, Ernstoff MS, Moschos SJ, Atkins MB, Postow M, Reardon DA, Grootendorst DJ, Askelson M, Ritchings C, Tawbi HA. Annals of Oncology, 2023 Oct; 34: s680 - s681.Journal Article1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
DOI:10.1016/j.annonc.2023.09.2269 -
Patel S, Othus M, Wright P, Hyngstrom J, Lao CD, Truong T-G, Chandra S, Kendra K, Devoe C, Hegde A, Mangla A, Lowe M, Buchbinder E, Kirkwood JM, Sharon E, Korde L, Moon J, Sondak VK, Ribas A, Prieto V. Annals of Oncology, 2023 Oct; 34: s1288Journal ArticleLBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801
DOI:10.1016/j.annonc.2023.10.042 -
Schadendorf D, Tawbi H, Lipson EJ, Stephen Hodi F, Rutkowski P, Gogas H, Lao CD, Grob J-J, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV. Eur J Cancer, 2023 Jul; 187: 164 - 173.Journal ArticleHealth-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
DOI:10.1016/j.ejca.2023.03.014 PMID: 37167764 -
Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Queirolo P, Smylie M, Butler MO, Hill AG, Marquez-Rodas I, Ritchings C, Sakkal LA, Wang P, Wolchok JD, Larkin J. Journal of Clinical Oncology, 2023 Jun 1; 41 (16_suppl): 9542 - 9542.Journal ArticleDurable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.
DOI:10.1200/jco.2023.41.16_suppl.9542 -
Schadendorf D, Tawbi HA, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao CD, Grob J-J, Ejzykowicz F, Moshyk A, Horton VG, Zhou J, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Sakkal LA, Long GV. Journal of Clinical Oncology, 2023 Jun 1; 41 (16_suppl): 9552 - 9552.Journal ArticleEfficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
DOI:10.1200/jco.2023.41.16_suppl.9552
